City of Hope Medical Center
cityofhope.orgTotal trials
654
Active
326
Phase 3
8
Total enrollment
1,077,746
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 40 of 273 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| trastuzumab | — | — | — | 9 | |||
| Trastuzumab Deruxtecan | — | — | — | — | — | 1 | |
| fluorouracil | — | — | 14 | ||||
| Bevacizumab | — | — | — | 7 | |||
| leucovorin calcium | — | — | 14 | ||||
| Mitomycin | — | — | — | 3 | |||
| irinotecan hydrochloride | — | — | 9 | ||||
| Extended Release Metformin Hydrochloride | — | — | — | — | — | 1 | |
| Cyclophosphamide | — | — | 58 | ||||
| Fludarabine | — | — | — | — | 20 | ||
| Tacrolimus | — | — | — | — | 23 | ||
| Nivolumab | — | — | — | — | 14 | ||
| Pembrolizumab | — | — | — | — | 18 | ||
| melphalan | — | — | 35 | ||||
| Venetoclax | — | — | — | — | 14 | ||
| etoposide | — | — | 29 | ||||
| Rituximab | — | — | — | 18 | |||
| Multi-peptide CMV-Modified Vaccinia Ankara Vaccine | — | — | — | 9 | |||
| Fludarabine Phosphate | — | — | — | 18 | |||
| carboplatin | — | — | — | — | 17 | ||
| Leflunomide | — | — | — | 10 | |||
| Mycophenolate Mofetil | — | — | — | 9 | |||
| Sirolimus | — | — | — | — | 13 | ||
| Brentuximab Vedotin | — | — | — | — | 9 | ||
| Gemcitabine | — | — | — | — | 6 | ||
| Prednisone | — | — | — | — | 5 | ||
| Acalabrutinib | — | — | — | — | — | 5 | |
| paclitaxel | — | — | — | 16 | |||
| oxaliplatin | — | — | — | — | 13 | ||
| Lenalidomide | — | — | — | — | 9 | ||
| paclitaxel albumin-stabilized nanoparticle formulation | — | — | — | — | 5 | ||
| Balstilimab | — | — | — | — | — | 5 | |
| Botensilimab | — | — | — | — | — | 5 | |
| Nab-paclitaxel | — | — | — | — | 4 | ||
| Doxorubicin | — | — | — | — | 4 | ||
| Obinutuzumab | — | — | — | — | 4 | ||
| busulfan | — | — | — | 11 | |||
| methotrexate | — | — | — | 6 | |||
| Cytarabine | — | — | — | 10 | |||
| doxorubicin hydrochloride | — | — | — | — | 9 |
233 more active programs hidden
Next readouts
- 2007-03-13
- 2010-04-12
- 2011-03-16
- 2011-10-25
- 2013-08-01
- 2013-10-03
- 2013-12-30
- 2013-12-30
- 2016-07-13
- 2017-05-17
Top conditions
- Breast Cancer41
- Acute Myeloid Leukemia28
- Myelodysplastic Syndrome27
- Unspecified Adult Solid Tumor, Protocol Specific26
- Lymphoma26
- Malignant Solid Neoplasm24
- Leukemia21
- Hematopoietic and Lymphoid Cell Neoplasm18
Frequently asked questions about City of Hope Medical Center
- How many clinical trials does City of Hope Medical Center have on ClinicalTrials.gov?
- City of Hope Medical Center is listed as the lead sponsor on 654 clinical trials in ClinicalTrials.gov, 326 of which are currently active (recruiting, enrolling, or ongoing).
- How many of City of Hope Medical Center's trials are in Phase 3?
- 8 of City of Hope Medical Center's trials are in Phase 3, spread across 273 active drug programs.
- What therapeutic areas does City of Hope Medical Center focus on?
- City of Hope Medical Center's most-studied conditions on ClinicalTrials.gov are Breast Cancer, Acute Myeloid Leukemia, Myelodysplastic Syndrome, Unspecified Adult Solid Tumor, Protocol Specific, Lymphoma.
- When are City of Hope Medical Center's next clinical trial readouts?
- City of Hope Medical Center has 10 upcoming primary-completion readouts tracked here; the soonest is “Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders”, expected around 2007-03-13.